Semaglutide compounding ingredient lot recalled over incomplete validation before distribution
Harbin Jixianglong Biotech is recalling a further lot of Semaglutide for prescription compounding because process validation and bacterial endotoxin method validation were not completed before distribution.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Rubric level 2 covers voluntary precautionary recalls: the source describes validation steps that were not completed rather than any contamination, hazard, illness or injury actually found.
Plain-English summary
Harbin Jixianglong Biotech Co., Ltd. is recalling Semaglutide, for prescription compounding use only, packaged in 1 g (NDC 84385-106-01), 5 g (84385-106-02), 10 g (84385-106-06), 25 g (84385-106-03) and 50 g (84385-106-04) sizes, manufactured in Harbin, China. The product was distributed nationwide within the United States. The FDA has classified this recall as Class II.
The recall was initiated for CGMP deviations, specifically failing to complete process validation and bacterial endotoxin method validation before distribution. The source record does not describe a specific hazard, illness or injury.
Affected product is lot CP-030-20250711, with an expiry date of 24 July 2027.
Compounding pharmacies can identify affected product by the NDC and lot number above, and may contact Harbin Jixianglong Biotech Co., Ltd. for further information.
The recalled product
- Product
- Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04 Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street…
- Manufacturer
- Harbin Jixianglong Biotech Co., Ltd.
- Category
- Drug — Compounding ingredient
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot #: CP-030-20250711
- Exp. Date Jul. 24th
- 2027
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Harbin Jixianglong Biotech Co., Ltd. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Harbin Jixianglong Biotech Co., Ltd.
See all →- ModerateSemaglutide compounding ingredient recalled over incomplete process and endotoxin validation
FDA (Drugs) · 2026-03-11
Same hazard · gmp deviation
See all →- HighPrazosin hydrochloride tablets recalled over nitrosamine impurity above limits
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride further lots recalled over nitrosamine impurity levels
FDA (Drugs) · 2026-04-08
- HighPrazosin hydrochloride 100-count bottles recalled over nitrosamine impurity
FDA (Drugs) · 2026-04-08
- ModerateFirst Aid Only hand sanitizing wipes recalled over manufacturing deviations
FDA (Drugs) · 2026-03-11
- ModerateFirst Aid Only BZK antiseptic towelettes recalled over manufacturing deviations
FDA (Drugs) · 2026-03-11
Similar recalls
- HighCompounded Semaglutide Recalled Due to Lack of Sterility Assurance
FDA (Drugs) · 2024-09-11
- HighCompounded semaglutide vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighCompounded semaglutide injection recalled due to sterility concerns
FDA (Drugs) · 2024-09-11
- HighCompounded Semaglutide Injection Vials Recalled for Sterility Concerns
FDA (Drugs) · 2024-09-11
- HighSemaglutide 10 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05
- HighSemaglutide 6 mg vials recalled for lack of sterility assurance
FDA (Drugs) · 2025-11-05